PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Biochim Biophys Acta. Author manuscript; available in PMC 2011 May 23.
Published in final edited form as:
PMCID: PMC3100204
NIHMSID: NIHMS177054

DARPP-32 binds to tra2-beta1 and influences alternative splicing

Abstract

The majority of human genes undergo alternative splicing, which is frequently altered in response to physiological stimuli. DARPP-32 (Dopamine and cAMP regulated phosphoprotein, 32 kD) is a component of PKA-dependent signaling pathways. Here we show that DARPP-32 binds directly to the splicing factor tra2-beta1 (transformer 2). DARPP-32 changes the usage of tra2-beta1 dependent alternative exons in a concentration dependent manner, suggesting that the DARPP-32:tra2-beta1 interaction is a molecular link between signaling pathways and pre-mRNA processing.

Introduction

Splicing

All polymerase II transcripts undergo pre-mRNA processing and at least 95% of the transcriptional units are alternatively spliced [1]. The exact regulation of alternative splicing events is physiologically important as evidenced by an increasing number of diseases shown to result from the selection of the wrong splice site [2, 3]. The proper recognition of alternative exons is regulated by the transient formation of protein complexes on the pre-mRNA that mark a sequence for its recognition by the spliceosome [4].

Tra2-beta1

Tra2-beta1 is one of the proteins that mark exonic sequences for inclusion in the mRNA. Tra2 was first discovered in drosophila where it regulates the sex development of flies and has been subsequently identified in all metazoan organisms [5, 6]. The protein consists of a central RNA recognition motif flanked by two serine-arginine rich protein domains that promote protein interactions. Tra2-beta1 generally promotes the inclusion of alternative exons in a concentration-dependent manner [7]. The protein contains an evolutionary conserved RVDF-binding motif in the beta4 strand of its RNA recognition motif, which allows tra2-beta1 to bind to protein phosphatase 1 (PP1) [8]. This motif corresponds to the consensus sequence found in most PP1 interacting proteins (RVXF) [9, 10]. The ability to bind to protein phosphatase 1 is essential for the function of tra2-beta1 in splice site selection [8] and a change in PP1 activity influences the splicing of a subset of alternative exons [8].

DARPP-32

Protein phosphatase 1 catalytic activity is tightly controlled in the cell. This control is achieved by sequestration of PP1 by targeting subunits and regulatory proteins that usually inhibit its activity. Only upon stimulation, the catalytic PP1 activity is released and PP1 dephosphorylates other proteins [11]. One of the inhibiting proteins is DARPP-32, for dopamine and cAMP regulated phosphoprotein, 32 kD. DARPP-32 is phosphorylated by PKA in response to an elevation of cellular cAMP levels and this phosphorylation causes a tight binding and inhibition of PP1. DARPP-32 was originally described as a cytosolic protein [12]. Recent results showed DARPP-32 accumulates in the nucleus after amphetamine or cocaine treatment. This accumulation blocked protein phosphatase 1 in the nucleus, leading to an increase of histone H3 phosphorylation [13].

Splicing and signaling

The usage of alternative exons can be altered by the cell, allowing for adaptations of the gene expression due to a stimulus [14, 15]. The molecular pathways that connect a change in gene expression caused by a different usage of alternative exons with cellular signaling pathways are only beginning to emerge. Numerous examples indicate that reversible phosphorylation of splicing factors plays a crucial role in this process [16]. Here, we show that DARPP-32, a well-known signaling molecule, interacts with the splicing factor tra2-beta1 and changes splice site selection of tra2-beta1 dependent exons. These results link DARPP-32 dependent signaling pathways with pre-mRNA processing events.

Material and Methods

Primary neuronal culture

Primary hippocampal cultures were prepared as described [17]. In brief, hippocampi were removed from Wistar rat embryos (E18). Cells were dissociated by mild trypsination (0.25% trypsin) in the presence of DNAse I (EC 3.1.21.1; 0.1 mg/mL) for 30 min. After addition of 10% fetal calf serum, dissociated cells were washed and resuspended in neurobasal medium containing l-glutamine and B-27 supplement (Gibco–BRL, Eggenstein, Germany) and plated on poly-l-lysine-coated (50 μg/mL) 6-well plates (3.5 ×106 cells per well), or on silanated and poly-l-lysine coated glass coverslips in 3-cm plates (1.5 × 105 cells per plate).

Cell culture and transfection

HEK293 cells were maintained in DMEM supplemented with 10% fetal calf serum (GibcoBRL). For immunolabeling experiments, cells were grown on glass coverslips in 3.5 cm cell culture dishes. The day before transfection, 3.0×105 HEK293 cells per 3.5 cm plate were seeded in 3 ml of DMEM and 10% FCS and incubated at 37°C in 5% CO2 for 24 h. Transient transfections of adherent HEK293 cells with cDNAs were performed using the calcium precipitation method as described [18].

Immunocytochemistry

HEK293 cells and primary hippocampal cultures were grown on coverslips. HEK293 cells were transfected with pEGFP-DARPP-32 and Tra2-beta1-Flag constructs overnight, washed in PBS at pH 7.4 and fixed in 4% para-formaldehyde for 20 min at 4°C. Permeabilization and blocking was for 30 min with 0.5% Triton X-100 and 3% Normal Goat Serum (Dianova) in PBS. Incubation with the anti-Tra2- or anti-DARPP-32 antiserum (1:200 in PBS, 0.3% NGS, 0.5% Triton X-100) was for 1h at 4°C. After washing three times for 10 min with PBS, the cells were incubated with a 1:200 dilution of a Cy3-coupled goat anti-rabbit-IgG antibody (Dianova) for 45 min. Untransfected neuronal cultures were fixed and incubated with primary antiserum as described above. After washing the cells were incubated with a goat anti-rabbit Cy-2 conjugated IgG (Dianova, 1:200) and a rabbit anti-goat Cy-3 conjugated IgG (Dianova, 1:300). Cells were washed three times in 1xPBS prior to mounting on microscope slides with Gel/Mount (Biomeda). The cells were examined by confocal laser scanning microscopy (Leica DMIRE2) using a HCX Plan Appochromat 100×1.4 CS oil immersion objective.

Coimmunoprecipitation and Western blots

were performed as described [19]. The following antibodies were used: polyclonal rabbit anti Tra2 (pan Tra2 beta) 1:1000 [20]; polyclonal goat anti-PP1 (C-19) 1:200 (Santa-Cruz biotechnology); polyclonal goat anti-DARPP-32 (N-19) 1:200 (Santa-Cruz biotechnology).

siRNA knockdown

The siRNA knockdown of DARPP-32 in HEK293 cells was performed using the reverse transfection procedure according to manufacturer’s (Qiagen, Hilden) direction on 6 well-plates. siRNAs for DARPP-32 (Santa Cruz sc-35173) were used as a pool of 3 target-specific 20–25 nt oligos at 5 nM final concentration. As a negative control scrambled siRNA-A (Santa Cruz sc-37007) was used. After 48 hours 1000 ng/well cDNA of the minigenes tau or tra2-beta expressing constructs were transfected as described earlier. RNA was isolated after 72 hours siRNA treatment (16–18 h after minigene transfection).

Protein purification and affinity isolation

Tra2-beta1 was purified from baculo virus infected cells as previously described [8]. DARPP-32 was purified from bovine brain as described [21]. Unbound protein was removed by native wash buffer 50mM NaH2PO4, 300mM NaCl, 20mM Imidazole, 0,1% Triton X-100, pH 8.0 in pull down assays.

Results

Tra2-beta1 binds to DARPP-32 in vivo

We previously showed that tra2-beta1 binds protein phosphatase 1 (PP1) via an evolutionary conserved PVXF motif in the RNA recognition motif of tra2-beta1 [8]. These findings suggested that PP1 is present in a complex with splicing factors. We next asked whether other PP1 interacting proteins could also interfere with splicing regulatory proteins. Unexpectedly, during these experiments we found that purified DARPP-32, a known PP1 interactor, binds to tra2-beta1. This was surprising, as a DARPP32:tra2-beta1 interaction has not been detected previously in yeast-two hybrid assays [6, 22]. We next confirmed these results by co-immunoprecipitation experiments and determined which protein domains are necessary for the interaction. Tra2-beta1 is composed of a central RNA binding motif flanked by two RS domains (Figure 1A). The RS domains are characterized by clusters of arginine-serine repeats and allow interaction between SR proteins. The RRM of tra2-beta1 binds to RNA and PP1. To investigate which tra2-beta1 protein parts are responsible for binding to DARPP-32 we performed immunoprecipitation experiments using tra2-beta1 variants lacking the first, second or both RS domains. As shown in Figure 1B, deletion of the first RS domain has no effect on DARPP-32 binding, whereas deletion of the second RS domain prevents binding.

Figure 1
Tra2-beta1 binds to DARPP-32 in vivo

To determine whether DARPP-32 can interact with endogenous tra2-beta1, we analyzed immunoprecipitates made from HEK239 cells that transiently express EGFP-DARPP-32. As shown in Figure 1C, we could detect endogenous tra2-beta1 in these immunoprecipitates, suggesting that the interaction can take place under physiological tra2-beta1 concentrations.

We next ask whether other SR-proteins could interact with DARPP-32 and coexpressed EGFP-tagged DARPP-32 with Flag-tagged SRp30c, SF2/ASF and SC35. As shown in Figure 1D-F, we could not detect these SR-proteins in the DARPP-32 immunoprecipitates.

Together, this data indicate that DARPP-32 binds to tra2-beta1 and that the second RS domain of tra2-beta1 is necessary for DARPP-32 binding. In contrast to tra2-beta1, several other SR-proteins do not interact with DARPP-32.

DARPP-32 colocalizes with tra2-beta1 in the nucleus of primary neurons

To investigate whether the interaction between DARPP-32 and tra2-beta1 could occur in cells, we performed double immunohistochemistry staining experiments using primary neuronal cultures. We used hippocampal neurons, which express low levels of DARPP-32 in vivo, but in which we found a significant labeling in culture. Neurons derived from E18 embryos were stained for endogenous DARPP-32 and tra2-beta1 after 14 days of culture. As shown in Figure 2, A–C both proteins show an overlapping staining in the nucleus. To determine whether there is a colocalisation in another cell type, we tested the localization of overexpressed DARPP-32 and endogenous tra2-beta1 in HEK293 cells. As shown in Figure 2E–G, in these cells DARPP-32 is primarily cytosolic, but can also be found in the nucleus, where DARPP-32 colocalizes with tra2-beta1. No staining was observed when the primary antisera were omitted (Figure 2D). Together, these results argue that both proteins colocalize in vivo and could indeed interact with each other.

Figure 2
tra2-beta1 colocalizes with DARPP-32

PP1 antagonizes the binding of DARPP-32 to tra2-beta1

We next tested whether the interaction between DARPP-32 and tra2-beta1 is direct and performed pull-down experiments using purified proteins. His-tra2-beta1 generated in insect cells [8] was coupled to Ni-agarose. This affinity matrix was incubated with purified DARPP-32. To rule out nucleic acid mediated interaction, benzonase was present in the binding reaction. The protein mixture was washed three times in Native Wash Buffer. After washing, protein was removed by boiling in 1% SDS and analyzed by PAGE followed by Western blot. As shown in Figure 3A, lane 4, this affinity resin bound DARPP-32. In contrast, no DARPP-32 was retained when no tra2-beta1 was prior bound to the resin (Figure 3A, lane 6). This experiment supports the interaction indicated by immunoprecipitation and shows that the binding between DARPP-32 and tra2-beta1 is based on direct protein:protein interaction.

Figure 3
DARPP-32 binds directly to tra2-beta1 and antagonizes PP1 binding to tra2-beta1

PP1 binds to both tra2-beta1 and DARPP-32 ([8], Figure 1, ,3).3). To test whether both proteins compete for PP1 binding, we incubated both PP1 and DARPP-32 with the tra2-beta1-affinity column. We found that the presence of PP1 reduced the amount of DARPP-32 bound to the column, (Figure 3A, lane 5). To further test whether DARPP-32 and PP1 compete for tra2-beta1 binding, we used different PP1 concentrations. The tra2-beta1 affinity matrix was loaded with purified DARPP-32 (50 μM), and subsequently half and equal molar amounts of PP1 were added. As shown in Figure 4B, lane 2 and 3, the added PP1 replaced DARPP-32 bound to tra2-beta1. Finally, we tested whether the PP1 binding site in the RRM of tra2-beta1 is involved in DARPP-32 binding and used tra2-beta1-RATA protein as an interacting partner. In this protein, the PP1 binding site in the beta4 strand of the RRM is changed from RVDF to RATA, which completely abolished PP1 binding [8]. As shown in Figure 3B, lane 4, DARPP-32 binds to tra2-beta1-RATA, indicating the PP1 binding site is not involved in DARPP-32 binding. Together, these data indicate that PP1 competes with DARPP-32 to bind to tra2-beta1.

Figure 4
DARPP-32 overexpression changes alternative splicing of reporter genes

DARPP-32 changes alternative splicing of tra2-beta1 dependent exons

Tra2-beta1 binds to GAA-rich sequences and generally promotes inclusion of alternative exons that contain such motifs [7]. We therefore determined whether DARPP-32 influences alternative splice site selection of two of such exons, the alternatively spliced exon 2 of the tra2-beta1 pre-mRNA and the tau exon 10 [7]. First, we transfected an increasing amount of DARPP-32 expression construct together with splicing reporter genes into HEK293 cells. As shown in Figure 4A–C, an increased amount of DARPP-32 caused skipping of the alternative exon in both the tau and tra2-beta1 reporter constructs, that paralleled the increase of DARPP-32 protein caused by the overexpression (Figure 4D).

We next performed the reverse experiment and removed DARPP-32 by siRNA treatment. As shown in Figure 5A–C, siRNA treatment promoted inclusion of both alternative exons, which again paralleled the decrease of DARPP-32 caused by siRNA treatment.

Figure 5
siRNA mediated DARPP-32 knock down changes alternative splicing of reporter genes

These experiment indicates that the relative concentration of DARPP-32 influences alternative splice site selection.

Discussion

DARPP-32 is a new interactor for tra2-beta1

Alternative splice site selection is regulated by reversible formation of protein complexes on pre-mRNA. Tra2-beta1 is a splicing regulatory protein that is present in all metazoa. Tra2-beta1 binds to other proteins via two domains that are rich in serine and arginine residues, the RS-domains. Previous studies showed interaction of tra2-beta1 with other typical RNA processing proteins, such as SR-proteins [6], hnRNP G and hnRNP G-like proteins [23, 24] as well as SAM68/p62 [25]. Recently, it was demonstrated that tra2-beta1 binds to protein phosphatase 1 via an evolutionary conserved binding site in its RNA recognition motif [8]. PP1 influences the phosphorylation status of tra2-beta1 and its ability to change splice site selection.

Here we describe that the PP1 interacting protein DARPP-32 binds to tra2-beta1. Both DARPP-32 and tra2-beta1 shuttle between nucleus and cytosol [13, 26] and staining of both proteins reveals a nuclear colocalisation, indicating that the interaction between the two proteins is physiologically relevant. The interaction between DARPP-32 and tra2-beta1 cannot be observed in yeast two hybrid systems (our unpublished data), which could indicate that post-translational modifications, such as proper phosphorylation patterns are required for the interaction. The binding between the two proteins is direct and most likely involves the C-terminus of tra-beta1. The tra2-beta gene generates two main proteins: tra2-beta1 and tra2-beta3. Tra2-beta1 contains two RS domains and tra2-beta3 lacks the first RS domain. Whereas tra2-beta1 has been shown to influence numerous alternative exons, the tra2-beta3 isoform does not change alternative exon usage. Our immunoprecipitation experiments indicate that tra2-beta3 binds DARPP-32. Similar to DARPP-32, the tra2-beta3 isoform is predominantly expressed in brain [6]. We therefore postulate that the function of this isoform is to sequester DARPP-32 without influencing splice site selection.

Upon proper phosphorylation, DARPP-32 inhibits PP1, which generally promotes exons that are dependent on splicing factors that contain PP1 binding sites, such as SF2/ASF and SRp30c [8]. In contrast to tra2-beta1, these two SR-proteins did not interact with DARPP-32 when analyzed by co-immunoprecipitation. This suggests that DARPP-32 has a special influence on tra2-beta1 dependent exons, as it sequesters tra2-beta1, but not other SR-proteins.

Functional implication

To test whether the binding of the two proteins has functional implications, we changed the concentration of DARPP-32 by overexpression and siRNA mediated knock down and tested the effect on two splicing reporter genes. We investigated the effect on tau exon 10 and exon 2 of the tra2-beta1 pre-mRNA, which are regulated by tra2-beta1 via a purine-rich motif. We found the DARPP-32 overexpression promotes alternative exon skipping upon overexpression, but favored exon inclusion when it is reduced by siRNA.

A change in intracellular DARPP-32 concentration does not affect every tra2-beta1 dependent alternative exon, as we did not see an effect when testing the CLK2, and SMN2 reporter genes that were previously shown to be regulated by tra2-beta1 [27, 28], (data not shown). This indicates that DARPP-32 concentrations influence a subset of alternative exons, which most likely share an similar arrangement of splicing regulatory factors. The exact mechanism of DARPP-32 action remains to be determined. We did not observe a shift in tra2-beta1 mobility on PAGE gels upon DARPP-32 overexpression, which argues against a global effect on the phosphorylation status, but it is possible that specific phosphorylation events are targeted.

The intracellular localization of DARPP-32 and its affinity to PP1 is regulated by protein kinase A in response to cellular stimulation. Our finding that DARPP-32 binds to tra2-beta1 and changes the processing of specific pre-mRNA connects cAMP-dependent signaling pathways emanating from the cell membrane with the regulation of nuclear RNA processing.

Acknowledgments

This work was funded by the NIH R21 grant HD056195 (AA and SS), the German research council (German-Israeli Project (DIP) to CMB, SS), STA399/8 and EURASNET (SS). Work in JA Girault laboratory is supported by Inserm and ANR-08-BLAN-0287-02.

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Literature

1. Pan Q, Shai O, Lee LJ, Frey BJ, Blencowe BJ. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat Genet. 2008;40:1413–1415. [PubMed]
2. Tazi J, Bakkour N, Stamm S. Alternative splicing and disease. Biochim Biophys Acta. 2009;1792:14–26. [PubMed]
3. Cooper TA, Wan L, Dreyfuss G. RNA and disease. Cell. 2009;136:777–793. [PMC free article] [PubMed]
4. Hertel KJ. Combinatorial control of exon recognition. J Biol Chem. 2008;283:1211–1215. [PubMed]
5. Mattox W, Baker BS. Autoregulation of the splicing of transcripts from the transformer-2 gene of Drosophila. Genes Dev. 1991;5:786–796. [PubMed]
6. Nayler O, Cap C, Stamm S. Human transformer-2-beta gene (SFRS10): complete nucleotide sequence, chromosomal localization, and generation of a tissue-specific isoform. Genomics. 1998;53:191–202. [PubMed]
7. Stoilov P, Daoud R, Nayler O, Stamm S. Human tra2-beta1 autoregulates its protein concentration by influencing alternative splicing of its pre-mRNA. Hum Mol Genet. 2004;13:509–524. [PubMed]
8. Novoyatleva T, Heinrich B, Tang Y, Benderska N, Butchbach ME, Lorson CL, Lorson MA, Ben-Dov C, Fehlbaum P, Bracco L, Burghes AH, Bollen M, Stamm S. Protein phosphatase 1 binds to the RNA recognition motif of several splicing factors and regulates alternative pre-mRNA processing. Hum Mol Genet. 2008:52–70. [PubMed]
9. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D. Structural basis for the recognition of regulatory subunits by the catalytic subunit of protein phosphatase 1. Embo J. 1997;16:1876–1887. [PubMed]
10. Meiselbach H, Sticht H, Enz R. Structural analysis of the protein phosphatase 1 docking motif: molecular description of binding specificities identifies interacting proteins. Chem Biol. 2006;13:49–59. [PubMed]
11. Ceulemans H, Bollen M. Functional diversity of protein phosphatase-1, a cellular economizer and reset button. Physiol Rev. 2004;84:1–39. [PubMed]
12. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004;44:269–296. [PubMed]
13. Stipanovich A, Valjent E, Matamales M, Nishi A, Ahn JH, Maroteaux M, Bertran-Gonzalez J, Brami-Cherrier K, Enslen H, Corbille AG, Filhol O, Nairn AC, Greengard P, Herve D, Girault JA. A phosphatase cascade by which rewarding stimuli control nucleosomal response. Nature. 2008;453:879–884. [PMC free article] [PubMed]
14. Stamm S. Signals and their transduction pathways regulating alternative splicing: a new dimension of the human genome. Hum Mol Genet. 2002;11:2409–2416. [PubMed]
15. Shin C, Manley JL. Cell signalling and the control of pre-mRNA splicing. Nat Rev Mol Cell Biol. 2004;5:727–738. [PubMed]
16. Stamm S. Regulation of alternative splicing by reversible phosphorylation. JBiol Chem. 2008;283:1223–1227. [PubMed]
17. Herkert M, Rottger S, Becker CM. The NMDA receptor subunit NR2B of neonatal rat brain: complex formation and enrichment in axonal growth cones. Eur J Neurosci. 1998;10:1553–1562. [PubMed]
18. Stoss O, Stoilov P, Hartmann AM, Nayler O, Stamm S. The in vivo minigene approach to analyze tissue-specific splicing. Brain Research Protocols. 1999;4:383–394. [PubMed]
19. Hartmann AM, Nayler O, Schwaiger FW, Obermeier A, Stamm S. The interaction and colocalization of Sam68 with the splicing- associated factor YT521-B in nuclear dots is regulated by the Src family kinase p59(fyn) Mol Biol Cell. 1999;10:3909–3926. [PMC free article] [PubMed]
20. Daoud R, Da Penha Berzaghi M, Siedler F, Hubener M, Stamm S. Activity-dependent regulation of alternative splicing patterns in the rat brain. Eur J Neurosci. 1999;11:788–802. [PubMed]
21. Hemmings HC, Jr, Nairn AC, Aswad DW, Greengard P. DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. II. Purification and characterization of the phosphoprotein from bovine caudate nucleus. J Neurosci. 1984;4:99–110. [PubMed]
22. Beil B, Screaton G, Stamm S. Molecular cloning of htra2-beta-1 and htra2-beta-2, two human homologs of tra-2 generated by alternative splicing. DNA Cell Biol. 1997;16:679–690. [PubMed]
23. Heinrich B, Zhang Z, Raitskin O, Hiller M, Benderska N, Hartmann AM, Bracco L, Elliott D, Ben-Ari S, Soreq H, Sperling J, Sperling R, Stamm S. hnRNP G regulates splice site selection by binding to CC(A/C)-rich regions in pre-mRNA. JBiol Chem. 2009;284:14303–14315. [PubMed]
24. Venables JP, Elliott DJ, Makarova OV, Makarov EM, Cooke HJ, Eperon IC. RBMY, a probable human spermatogenesis factor, and other hnRNP G proteins interact with Tra2beta and affect splicing. Hum Mol Genet. 2000;9:685–694. [PubMed]
25. Venables JP, Vernet C, Chew SL, Elliott DJ, Cowmeadow RB, Wu J, Cooke HJ, Artzt K, Eperon IC. T-STAR/ÉTOILE: a novel relative of SAM68 that interacts with an RNA-binding protein implicated in spermatogenesis. Human Molecular Genetics. 1999;8:959–969. [PubMed]
26. Daoud R, Mies G, Smialowska A, Oláh L, Hossmann K, Stamm S. Ischemia induces a translocation of the splicing factor tra2-beta1 and changes alternative splicing patterns in the brain. J Neurosci. 2002;22:5889–5899. [PubMed]
27. Glatz DC, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, Rosenberg C, Hulette C, Jellinger K, Hampel H, Riederer P, Moller HJ, Andreadis A, Henkel K, Stamm S. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer’s disease. J Neurochem. 2006;96:635–644. [PubMed]
28. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2) Proc Natl Acad Sci U S A. 2000;97:9618–9623. [PubMed]